Kotagal Kant

Kotagal S Kant , MD

Professor of Clinical

Medical Sciences Building
Room G163A
231 Albert Sabin Way
Cincinnati, Ohio 45267
Phone 513-558-5471
Fax 513-558-4309
Email shashi.kant@uc.edu

Education

Medical Degree: All India Institute of Medical Sciences Delhi, ID, 1970

Residency: Michael Reese Hospital and Medical Center Chicago, IL, 1974 (Internal Medicine)

Fellowship: University of Cincinnati Cincinnati, OH, 1976 (Nephrology)

Certifications

American Board of Internal Medicine (Certification Date: 06-19-1974 )

American Board of Internal Medicine (Nephrology) (Certification Date: 10-19-1976 )

Clinical Interests

Nephrology

Acute Kidney Injury (AKI)

Acute Renal failure (Acute kidney failure)

Specialities

Internal Medicine

Nephrology

Research and Practice Interests

Calcium, Phosphorus and Bone Metabolism, Acid Base Changes in Hemodialysis, Glomerular Disease, Vascular Disease in CKD/ESRD: Role of Dialysis Adequacy, Thrombophilia and Mineral Metabolism Abnormalities

Positions and Work Experience

1971 - House Physician in Medicine, All India Institute of Medical Sciences, New Delhi, India

1976 -1977 Instructor of Medicine, University of Cincinnati Medical Center, Cincinnati, OH

1977 - Assistant Professor of Medicine, University of Cincinnati Medical Center, Cincinnati, OH

1983 - Associate Professor of Clinical Medicine, University of Cincinnati Medical Center, Cincinnati, OH

1989 - Professor of Clinical Medicine, University of Cincinnati Medical Center, Cincinnati, OH

Research Support

2010 A Prospective, Multicenter, Randomized, Evaluator-blinded, Comparator-controlled Study to Describe the Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin Structure Infections (CSSSI) and Staphylococcus aureus Bacteremia Among Subjects with Moderate or Severe Renal Impairment Role:PI

2010 A 4-week Dose-Ranging and Efficacy Trial of KRX-0502 (ferric citrate) in Patients with End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period Role:PI

2010 A Phase II Randomized, Open-Label, Multiple-Rising Dose clinical Trial to Study the Efficacy and Safety of MK-2578 for the Maintenance of Anemia Treatment in Patients with Chronic Kidney Disease Who are on hemodialysis Role:Sub-I

2010 An open, randomized, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and lanthanum carbonate together with a randomized placebo controlled double blind fermagate comparison in hemodialysis patients with hyperphosphatemia Role:Sub-I

Investigators:Kotagal Shashi Kant 2009 A single-dose, open-label, dose determination, randomized, cross-over, pharmacokinetic study of CTAP201 injection and doxercalciferol (Hectorol) injection in subjects with stage 5 chronic kidney disease and secondary hyperparathyroidism on hemodialysis Role:PI Completed

Investigators:Kotagal Shashi Kant 2009 A phase 2, randomized, open-label, single-dose study of oral and intravenous CTAP101 evaluating pharmacokinetics, pharmacodynamics, and safety in subjects with stage 3 and 4 chronic kidney disease, with vitamin D insufficiency and secondary hyperparathyroidism Role:PI Completed

Investigators:Kotagal Shashi Kant 2009 A randomized, double-blind, placebo-controlled, dose-ranging study using Genz-644470 and sevelamer carbonate in hyperphosphatemic chronic kidney disease patients on hemodialysis Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2008 A randomized, single-blind, placebo-controlled, 4-week treatment study of the safety and biologic activity of escalating multiple oral dose of FG-4592 in subjects with chronic kidney disease not requiring dialysis Role:PI Completed

Investigators:Kotagal Shashi Kant 2008 A phase 1-2, multiple-center, dose escalation study of a single dose of PRT-201 administered immediately after arteriovenous fistula creation in patients with chronic kidney disease Role:PI Completed

Investigators:Kotagal Shashi Kant 2008 A 30-week, multicenter, randomized, double-blind, parallel-group study of the combination of ABT-335 and rosuvastatin compared to rosuvastatin mono-therapy in dyslipidemic subjects with stage 3 chronic kidney disease Role:PI Completed

Investigators:Kotagal Shashi Kant 2008 A multi-center, randomized, controlled study to investigate the safety and tolerability of intravenous ferric carboxymaltose (FMC) vs. standard medical care in treating iron deficiency anemia in chronic kidney disease pateints Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2008 A multi-center, randomized, double-blind study to evaluate the efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes mellitus and end-stage renal disease who are on dialysis and who have inadequate glycemic control Role:PI Completed

Investigators:Kotagal Shashi Kant 2008 A phase 2/3, randomized, double-blind study to evaluate the safety and efficacy of atacicept in subjects with class III or IV lupus nephritis in combination with myophenolate mofetil therapy Role:PI Completed

Investigators:Kotagal Shashi Kant 2008 Safety and efficacy of vascugel treatment after the creation of arteriovenous access for hemodialysis use - and extension study Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2008 A multi-center, randomized, double-blind, active-controlled clinical trial to evaluate the safety and tolerablity of 24 weeks tretment with vildagliptin (50 mg gd) versus sitagliptin (25 mg qd) in patients with type 2 diabetes and sever renal insufficiency Role:PI Completed

Investigators:Kotagal Shashi Kant 2008 A phase 3, randomized, active-controlled, open-label, multi-center study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin alfa Role:PI Completed

Investigators:Kotagal Shashi Kant 2007 A randomized, single blind trial to assess the effectiveness of maintaining patency and safety of the paclitaxel-eluting vascular wrap after surgical implantation with the lifespan graft in the upper extremity for hemodialysis vascular access (Angiotech) Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2007 A phase III, randomized, double-blind, placebo-controlled study of AST-120 for prevention pf chronic kidney disease progression in patients with moderate to severe chronic kidney disease including assessment of quality of life Role:PI Completed

Investigators:Kotagal Shashi Kant 2007 Shire SELECT A phase IV, long-term, observational safety study in end stage renal disease subjects treated with lanthanum carbonate (Fosrenol) Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2006 HAPPI: hemodialysis access patency extension with percutaneous transluminal infusion of dexamethasone Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2006 EVOLVE: evaluation of cinacalcet HCL therapy to lower cardiovascular events Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2006 ADVANCE: a randomized study of evaluate the effects of ciacalcet plus low dose vitamin D on vascular calcification in subjects with chronic kidney disease (CKD) receiving hemodialysis Role:PI Completed

Investigators:Kotagal Shashi Kant 2006 A phase 4, multi-center, open-label, randomized study to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Hectorol (doxercalciferol injection) for the treatment of secondary hyperparathryroidism in stage 5 chronic kidney disease (CKD) subjects on hemodialysis Role:PI Completed

Investigators:Kotagal Shashi Kant 2006 A randomized, single blind trial to assess the effectiveness of maintaining patency and safety of the palitaxel-eluting vascular wrap after surgical implantation with the lifespan graft in the upper extremity for hemodialysis vascular access Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2006 Chart review: hemodialysis catheters and infection control Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2006 Safety of vascugel in the creation of arteriovenous access for hemodialysis use Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2006 A phase 2 randomized study of the safety and efficacy of FG-2216 in subjects with renal anemia not requiring dialysis and not receiving recombinant human erythropoietin Role:PI Completed

Investigators:Kotagal Shashi Kant 2005 A pilot phase II trial of ABI-007 (a Cremophor -free, protein stabilized, nanoparticle paclitaxel) for the preventing of vascular access graft failure in patients undergoing hemodialysis Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2005 A phase-IV, open-label, multi-center trial evaluating the efficacy of Fosrenol compared to existing therapy in adults wiuth end stage renal disease treated for hyperphosphatemia Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2005 An open-label, multiple-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia Role:PI Completed

Investigators:Kotagal Shashi Kant 2004 Potassium channels in lymphocytes: comparison between patients with lupus erythematosus and other autoimmune diseases and normal controls Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2004 Trial to reduce cardiovascular events with aranesp therapy (TREAT) Role:PI Completed

Investigators:Kotagal Shashi Kant 2004 A phase 3, randomized, placebo-controlled, double-blind, multi-center study to evaluate the study and efficacy of Zemplar Capsule in reducing serum intact parathyroid hormone levels in chronic kidney disease stage 5 subjects on hemodialysis or peritoneal dialysis Role:PI Completed

Investigators:Kotagal Shashi Kant 2004 A phase III study of the safety and efficacy of Ferumoxytol (compared with oral iron) as an iron replacement therapy in chronic kidney disease for patients not on dialysis Role:p Completed

Investigators:Kotagal Shashi Kant 2004 A phase 3, multicenter, randomized, placebo-controlled, double-blinded study to evaluate efficacy of StaphVAX, a bivalent staphylococcus aureus glycoconjugate vaccine in adults on hemodialysis Role:PI Completed

Investigators:Kotagal Shashi Kant 2004 A randomized, controlled, open-label, multi-center, parallel-group center study to demonstrate the efficacy and the safety of RO0503821 when administered intravenously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis Role:PI Completed

Investigators:Kotagal Shashi Kant 2004 A study of the efficacy and safety of Venofer [iron sucrose injection] in anemic patients peritoneal dialysis Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2004 A phase IV, prospective, randomized, active-controlled, double-blind, double-dummy, multi-center study to evaluate the survival benefits of Zemplar relative to Calcijex in subjects with stage V chronic kidney disease on hemodialysis Role:PI Completed

Investigators:Kotagal Shashi Kant 2004 Potassium channels in lymphocytes: a comparison between patients with systemic lupus erythematosus other autoimmune diseases and normal controls Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2003 Multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of the effects of oral tolvaptan in patients in patients with hyponatremia Role:PI Completed

Investigators:Kotagal Shashi Kant 2003 A multicenter, randomized, open-label study to compare the efficacy and safety of an oral calcimimetic agent (AMG 073) when two different vitamin D regimens are used in subjects with secondary hyperpaprathyroidism of end-stage renal disease (ESRD) Role:PI Completed

Investigators:Kotagal Shashi Kant 2003 A study of the efficacy and safety of Venofer [iron sucrose injection] in anemic patients receiving peritoneal dialysis (Luitpold) Role:PI Completed

Investigators:Kotagal Shashi Kant 2002 A randomized, double-blind study comparing aranesp (darbepoetin alfa) and recombinant human erythropoietin (rHuEPO) in the treatment of anemia in african-american subjects with chronic renal failure (CRF) receiving hemodialysis Role:PI Completed

Investigators:Kotagal Shashi Kant 2002 A placebo-controlled, double-blind, extension study to assess the long-term safety of an oral calcimimetic agent (AMG 073) in secondary hyperparathyroidism of end-stage renal disease Role:PI Completed

Investigators:Kotagal Shashi Kant 2002 Correction of hemoglobin and outcomes in renal insufficiency (CHOIR) Role:PI Completed

Investigators:Kotagal Shashi Kant 2002 PROCRIT for maintenance phase treatment (PROMPT) Role:PI Completed

Investigators:Kotagal Shashi Kant 2002 Beta radiation for treatment of arterial - venous graft outflow (BRAVO) Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2002 A phase III, prosepctive, randomized, placebo-controlled, double blind, multi-center study to determine the safety and efficacy of zemplar capsules (dosed three times weekly) in reducing elevated serum intact parathyroid hormone levels in subjects with chronic kidney disease Role:PI Completed

Investigators:Kotagal Shashi Kant 2002 A prospective trial of the biolink dialock access to evaluate its safety and effectiveness in chronic hemodialysis, study (biolink) Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 2001 A phase 3 study to assess the efficacy and safety of an oral calcimietic agent (AMG 073) in secondary hyperparathyroidism of end stage renal disease treated with hemodialysis (Amgen) Role:PI Completed

Investigators:Kotagal Shashi Kant 2000 Prevalence of anemia in patients with early renal insufficiency, (ortho biotech) Role:PI Completed

Investigators:Kotagal Shashi Kant 2000 Clinical evaluation of PROCRIT (epoetin alfa) dosed once weekly in patients with anemia due to early renal insufficiency (POWER) (ortho biotech) Role:PI Completed

Investigators:Kotagal Shashi Kant 2000 A study evaluating the initiation and titration of fixed dosed of novel erythropoiesis stimulating protein (NESP) therapy in subjects with chronic renal insufficiency (CRI) (amgen) Role:PI Completed

Investigators:Kotagal Shashi Kant 1998 Safety and efficacy of intravenous HMR4396 and epogen for the management of anemia in subjects with chronic renal faliure requiring dialysis (aventis) Role:PI Completed

Investigators:Kotagal Shashi Kant 1998 Safety and efficacy of subcutaneous HMR4396 for the management of anemia in subjects with chronic renal failure (predialysis, hemodialysis, peritoneal dialysis) (aventis) Role:PI Completed

Investigators:Kotagal Shashi Kant 1998 Phase III randomized study comparing external beam radiation versus observation only, following angioplasty for prevention of restenosis in hemodialysis patients Role:Sub-I Completed

Investigators:Kotagal Shashi Kant 1996 An extended use study of renagel in hemodialysis patients (geltex) Role:PI Completed

Investigators:Kotagal Shashi Kant 1996 CHOICE (choices for healthy outcomes in caring for ESRD) cohort study (john hopkins) Role:PI Completed

Investigators:Kotagal Shashi Kant 1996 Phase III comparison between 19-nor-1 alpha, 25-dihydroxyvitamin D2 and intravenous calcitriol in end stage renal disease patients undergoing hemodialysis patients (abbot) Role:PI Completed

Investigators:Kotagal Shashi Kant 1996 An open-label, cross-over study of renalgel and calcium acetate in hemodialysis patients (geltex) Role:PI Completed

Investigators:Kotagal Shashi Kant 1994 Kidney foundation of greater cincinnati Role:PI Completed

Investigators:Kotagal Shashi Kant 1987 R. P. Scherer corporation, EPA supplements: "Effect on normal monocyte function" Role:PI Completed

Investigators:Kotagal Shashi Kant 1986 Kidney foundation of greater cincinnati Role:PI Completed

Investigators:Kotagal Shashi Kant 1983 American heart association (S. W. Ohio chapter) "endothelial dysfunction in nephritis" Role:PI Completed

Investigators:Kotagal Shashi Kant National co-operative erythropoietin study in patients with chronic renal failure Role:Co-PI Completed

Investigators:Kotagal Shashi Kant UNIVAX - staphylococcal vaccine trial Role:Co-PI Completed

2011 A Randomized, Double-Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of XXX in Subjects with Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism Role:PI

2011 A Randomized, Double-Blinded, Placebo-Controlled, Phase III Study of Dialysate Containing XXX in Chronic Kidney Disease Patients Receiving Hemodialysis: The Continuous Replacement Using Iron Soluble Equivalents Study Role:Sub-Investigator

2011 XXX Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events Role:PI

2011 A Multi-Center, Longitudinal, Observational Study of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression Role:PI

2011 An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized with Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization (Sub-Investigator) Role:Sub-Investigator

2011 (REPAIR-IDA): Randomized Evaluation of Efficacy and Safety of XXX Patients with Iron Deficiency Anemia and Impaired Renal Function Role:Sub-Investigator

2011 A Three-Period, 58-Week Safety and Efficacy Trial of XXX in Patients with End-Stage Renal Disease (ESRD) on Dialysis Role:PI

2011 Burden of AV Graft and Fistula Complications in Chronic Kidney Disease (GRAFIC) Role:PI

2012 -To Present A Long-Term Safety Extension Trial of XXX in Patients with End Stage Renal Disease (ESRD) on Dialysis Role:PI

2012 -To Present A Long-Term Safety Extension Trial in XXX Patients with End-Stage Renal Disease (ESRD) on Dialysis Role:PI

2012 -2013 A Therapeutic-Equivalence Study Comparing the Efficacy and Safety of Subcutaneous XXX and YYY in Patients with Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment Role:PI

2013 -To Present A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of XXX in the Treatment of Secondary Hyperparathyroidism in Subjects with Chronic Kidney Disease on Hemodialysis Role:PI

2013 -To Present Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of XXX in Subjects with Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, and 5) (Pre-Dialysis) Role:Sub-Investigator

2013 -To Present A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of XXX on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy - SONAR: Study of Diabetic Nephropathy with Astrasentan Role:Sub-Investigator

2013 -To Present A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound xxxx in Secondary Hyperparathyroidism in Patients on Hemodialysis Role:PI

2013 -To Present A Phase III, Open-Label, Multicenter, Long-Term Safety Study of Subcutaneous xxx in Patients with Chronic Renal failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment Role:PI

2013 -To Present A Multicenter Single-Arm Extension Study to Describe the Long-term Efficacy and Safety of xxx in the Treatment of Secondary Hyperparathyroidism in Subjects with Chronic Kidney Disease on Hemodialysis Role:PI

2013 -To Present A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of xxx with Intravenous Doses of yyy in Hemodialyis Subjects with Secondary Hyperparathyroidism Role:PI

2013 -To Present A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety or Oral xxx and Active Comparator (yyy) in the Maintenance Treatment of Subjects with Anemia Associated with Chronic Kidney Disease Who are on Dialysis and on Treatment with an Erythropoieses-stimulating Agent in the United States and Japan Role:Sub-Investigator

2013 -To Present A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-daily Administration of a Chemokine ccr2/5 Receptor Antagonist (xxx) in Adults with Type 2 Diabetes and Overt Nephropathy Role:Sub-Investigator

2013 -To Present A Controlled, Parallel Group, Open-Label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral xxx and Active Comparator (yyy) in the Long-Term Treatment of Subjects with Anemia Associated with Chronic Kidney Disease who are on Dialysis in the United States and Japan Role:Sub-Investigator

Publications

Published Abstracts

Kant KS, Pesce AJ, Clyne DH, Pollak VE (1977. ) Coprecipitation of Tamm-Horsfall protein with myoglobin hemoglobin and Bence-Jones proteins .[Abstract]Clin Res, 25 ,594A

Glas-Greenwalt P, Kant KS, Allen C, Dosekun AK, Pollak VE (1982. ) Impaired fibrinolysis in systemic lupus erythematosus and thrombotic thrombocytopenic purpura .[Abstract]Clin Res, 30 ,502A

Kant KS, Glas-Greenwalt P, Sexton J, Pollak VE (1984. ) Endothelial cell plasminogen activator production: Effect of mediators of inflammation .[Abstract]Clin Res, 32 ,349A

Glas-Greenwalt P, Olinger CP, Kant KS, Healy L, Pollak VE (1984. ) Severe abnormalities of the fibrin-clearing in multiple sclerosis .[Abstract]Clin Res, 32 ,496A

Du Xo-H, Glas-Greenwalt P, Kant KS, Pollak VE (1984. ) Nephrotic syndrome with renal vein thrombosis: Pathogenetic importance of a plasmin inhibitor .[Abstract]Clin Res, 32 ,445A

Kant KS, Duncan HJ, Tallarico BJ, McKinney RA, Diadato CL (2008. ) Does the buttonhole technique of AV fistula cannulation increase risk of bacteremia? .[Abstract]Amer Soc Neph, 19 ,262ACo-Author

Kant KS, El-Khatib MT, Duncan HJ (2009. ) Use of Antibiotic-Locking Solutions to Decrease Hemodialysis Catheter Related Bacteremia: Long-Term Impact on CRB Rates and Bacterial Resistance .[Abstract]Amer Soc Neph,

Nicolaou S, Szigletti P, Duncan H, Neumeier L, Lee S, Kant K, Filipovich A, Conforti L (2006. ) Altered dynamics of Kv 1.3 channel compartmentalization in the immunological synapse in SLE .[Abstract]J Clinical Immunology, 119 ,568Co-Author

Peer Reviewed Publications

Kant, K Shashi; Gonzalez, Alejandro R; Hariachar, Srinivas; Bernardo, Marializa; Duggal, Ajay; Engstrand, Sara; Hunter, John; Plone, Melissa; Hertel, Joachim (2011. ) Converting to Doxercalciferol Capsules From Intravenous Paricalcitol or Doxercalciferol.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, , More Information

Lal, Vivek; Kant, Shashi; Dewan, Richa; Rai, Sanjay K; Biswas, Ashutosh A two-site hospital-based study on factors associated with nonadherence to highly active antiretroviral therapy.Indian journal of public health, , 54 (4 ) ,179-83 More Information

Kant, Shashi; Haldar, Partha Is NDM-1 actually being imported to UK from India?.Indian journal of public health, , 54 (3 ) ,151-4 More Information

Nicolaou, Stella A; Neumeier, Lisa; Takimoto, Koichi; Lee, Susan Molleran; Duncan, Heather J; Kant, Shashi K; Mongey, Anne Barbara; Filipovich, Alexandra H; Conforti, Laura (2010. ) Differential calcium signaling and Kv1.3 trafficking to the immunological synapse in systemic lupus erythematosus.Cell calcium, , 47 (1 ) ,19-28 More Information

Nicolaou, Stella A; Szigligeti, Peter; Neumeier, Lisa; Lee, Susan Molleran; Duncan, Heather J; Kant, Shashi K; Mongey, Anne Barbara; Filipovich, Alexandra H; Conforti, Laura (2007. ) Altered dynamics of Kv1.3 channel compartmentalization in the immunological synapse in systemic lupus erythematosus. Journal of immunology (Baltimore, Md. : 1950), , 179 (1 ) ,346-56

Pandey, Arvind; Thomas, M; Reddy, D C S; Kant, Shashi; Bhattacharya, M Process of estimating the number of people living with HIV in India. Indian journal of public health, , 51 (1 ) ,7-13

Duncan, Heather J; Pittman, Susan; Govil, Amit; Sorn, Lisa; Bissler, Gloria; Schultz, Tersea; Faith, J; Kant, Shashi; Roy-Chaudhury, Prabir (2007. ) Alternative medicine use in dialysis patients: potential for good and bad!.Nephron. Clinical practice, , 105 (3 ) ,c108-13 More Information

El-Khatib, Mahmoud; Duncan, Heather J; Kant, K Shashi (2006. ) Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.Nephrology (Carlton, Vic.), , 11 (5 ) ,400-4 More Information

Malhotra, Sumit; Kant, Shashi Adverse female-to-male sex ratio at birth in India: a cause for concern. The National medical journal of India, , 19 (3 ) ,152-4

Kant, Shashi Choices of ecosystem capital without discounting and prices. Environmental monitoring and assessment, , 86 (1-2 ) ,105-27

Kant, K Shashi; Cook, E Francis; Duncan, Heather; Freyberg, Ron (2002. ) Parathyroid hormone suppression by intravenous calcitriol: role of phosphate, calcium, race and diabetes. The American journal of the medical sciences, , 323 (4 ) ,210-5

Ooi BS, Kant KS, Hanenson IB, Pesce AJ, Pollak VE (1977. ) Lymphocytotoxins in epileptic patients receiving phenytoin .Clin Exp Immunol, , 30 ,56-61

Pesce AJ, Kant KS, Ooi BS, Pollak VE (1978. ) The application of enzyme immunoassay in the diagnosis of autoimmune diseases .Scand J Immun, , 8 (suppl 7) ,91-96

Pesce AJ, Kant KS, Hanenson IB, Pollak VE (1978. ) Autoimmunity and systemic lupus erythematosus .Clinical Immunochemistry, ,

Clyne DH, Kant KS, Pesce AJ, Pollak VE (1979. ) Nephrotoxicity of low molecular weight serum proteins: Physiochemical interactions between myoglobin, hemoglobin, Bence-Jones proteins and Tamm-Horsfall mucoprotein .Curr Probl Clin Biochem, , (299-308 ) ,

Pesce AJ, Clyne DH, Pollak VE, Kant, KS (1980. ) Renal tubular interactions of proteins .Clin Biochem, , 13 ,209-215

Kant KS, Pollak VE, Goetz D, Cathey M (1980. ) Dialyzer reuse: a long-term study of safety and efficacy at one center .Proc Clin Dial Transplant Forum, , 10 ,35-38

Pollak VE, Kant KS (1981. ) Nephritis in systemic lupus erythematosus (natural history, treatment and pathogenesis) .Ric Clin Lab, , 11 ,1-10

Ooi BS, Weiss MA, Kant KS, Hong CF, Pollak VE, Andriole VT (1981. ) Antibody to Tamm-Horsfall protein after acute tubular necrosis .Am J Nephrol, , 1 ,48-51

Kant KS, Pollak VE, Weiss MA, Glueck HI, Miller AN, Hess EV (1981. ) Glomerular thrombosis in systemic lupus erythematosus: Prevalence and significance .Medicine (Baltimore), , 60 ,71-86

First MR, Munda R, Kant KS, Fidler JP, Alexander JW (1981. ) Steroid withdrawal following HLA-identical related donor transplantation .Transplant Proc, , 13 ,319-322

Kant KS, Pollak VE, Cathey M, Goetz D, Berlin R (1981. ) Multiple use of dialyzers: Safety and efficacy .Kindey Int, , 19 ,728-138

Grant KD, Kant KS, Pollak VE, Weiss MA, Hess EV (1982. ) Thrombosis in the lupus kidney .Arthritis Rheum, , 25 ,117

Dosekun AK, First MR, Chandran PK, Kant KS, Glas-Greenwalt P, Weiss MA, Alexander JW, Pollak VE (1982. ) Successful treatment by defibrination with ancrod in a patient with hyperacute renal allograft failure and a deficiency of plasma prostacyclin stimulating factor .Clin Nephrol, , 18 ,101-105

Kant KS, Dosekun AK, Chandran KG, Glas-Greenwalt P, Weiss MA, Pollak VE (1982. ) Deficiency of a plasma factor stimulating vascular prostacyclin generation in patients with lupus nephritis and glomerular thrombi and its correction by ancrod: Ino-vivo and in-vitro observations .Thromb Res, , 27 ,641-658

Dosekun AK, Pollak VE, Glas-Greenwalt P, Kant KS, Penovich P, Lebron-Berges A, Weiss MA, Levinson JE (1984. ) Ancrod in systemic lupus erythematosus and with thrombosis: clinical and fibrinolysis effects .Arch Intern Med, , 44 ,37-42

Glas-Greenwalt P, Kant KS, Allen C, Pollak VE (1984. ) Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus .J Lab Clin Med, , 104 ,962-976

Kant KS, Pollak VE, Dosekun A, Glas-Greenwalt P, Weiss MA, Glueck HI (1985. ) Lupus nephritis with thrombosis and abnormal fibrinolysis: Effect of ancrod .J Lab Clin Med, , 105 ,77-88

Glueck HI, Kant KS, Weiss MA, :Pollak VE, Miller MA, Coots M (1985. ) Thrombosis in systemic lupus erythematosus: Relation to the presence of circulating anicoagulants .Arch Intern Med, , 145 ,1389-1395

Glas-Greenwalt P, Kant KS, Dosekun A, Frazier J, Allen C, Pollak VE (1985. ) Ancros: Normalization of fibrinolyti enzyme abnormalities in patients with systemic lupus erythematous and lupus nephritis .J Lab Clin Med, , 105 ,99-107

Garcia G, Deddens JA, D-Achiardi-Rey R, First MR, Samuels SJ, Kant KS, Pollak VE (1985. ) Results of treatment in patients with end-stage renal disease: A multivariate analysis of risk factors and survival in 341 successive patients .Am J Kidney Disease, , 5 ,10-18

Du X-H, Glas-Greenwalt P, Kant KS, Allen CM, Hayes S, Pollak VE (1985. ) Nephrotic syndrome with renal vein thrombosis: Pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin) .Clin Nephrol, , 24 ,186-191

Robson MD, Charoenpanich R, Kant KS, Peterson DW, Flynn J, Cathey M, Pollak VE (1986. ) Effect of first ans subsequent use of hemodialyzers on patient well-being: Analysis of the incidence of symptoms and events and description of a syndrome associate with new dialyzer use .Am J Nephrol, , 6 ,101-106

Pollak VE, Kant KS, Parnell SL, Levin NW (1986. ) Repeated use of dialyzers is safe: Long-term observations on morbidity and mortality in patients with end-stage renal disease .Nephron, , 42 ,217-223

Glas-Greenwalt P, Hall JM, Panke TW, Kant KS, Allen CM, Pollak VE (1986. ) Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen inhibitor, and protein C in thrombotic thrombocytopenic purpura .J Lab Clin Med, , 108 ,415-422

Charoenpanich R, Pollak VE, Kant KS, Robson MD, Cathey M, (1987. ) Effect of first and subsequent use of hemodialyzers on patient well-being: The rise and fall of a syndrome associated with new dialyzer use .Artif Organs, , 11 ,123-127

Pollak VE, Kant KS (1987. ) Autoimmune glomerulonephritis: An approach to certain pathogenetic factors and their relation to treatment .Clin Aspect of Autoimmunity, , 1 ,2-11

Pollak VE, Charoenpanich R, Robson M, Kant KS (1988. ) Dialyzer membranes: syndromes associated with first use and effects of multiple use .Kindey Int, , Suppl 24 ,S49-S52

Kant KS, Goetz D, Marzluff C, Motz D (1988. ) Relapsing peritonitis in continuous ambulatory peritoneal dialysis (CAPD): Treatment by interruption of CAPD and prolonged antibiotic therapy .Perit Dial Int, , 8 ,155-157

Kim S, Washwa NK, Kant KS, Pollak VE, Glas-Greenwalt P, Weiss MA, Hong CG (1988. ) Fibrinolysis in glomerulonephritis treated with ancrod: Renal functional, immunologic and histopathologic effects .Q J Med, , 69 ,879-905

First MR, Smith RD, Weiss, MA, Schroeder TJ, Kant KS, Minda R, Stephens GW, Penn I, Alexander JW (1989. ) Cyclosporine-associated glomerular and arteriolar thrombosis following renal transplantation .Transplant Proc, , 21 ,1567-1570

Kant, KS (1989. ) Treatment of recurrent peritonitis .Perit Dial Int, , 9 ,355

Sridhar NR, Thornley-Brown D, Kant K (1990. ) Peritonitis due to Aspergillus niger: diagnostic importance of peritoneal eosinophilia .Perit Dial Int, , 10 ,100-101

Hariharan S, Pollak VE, Kant KS, Weiss MA, Wadhwa NK (1990. ) Diffuse proliferative lupus nephritis: long-term observations in patients treated with ancrod .Clin Nephrol, , 34 ,61-69

Pollak VE, Kant KS, Hariharan S (1991. ) Diffuse and focal proliferative lupus nephritis: Treatment approaches and results .Nephron, , 59 ,177-193

Kant KS, Glueck HI, Coots MC, Tonne VA, Brubaker R, Penn I (1992. ) Protein S deficiency and skin necrosis associated with continuous ambulatory peritoneal dialysis .Am J Kidney Disease, , 19 ,264-271

Thornley-Brown D, Galla JH, Williams PD, Kant KS, Rashkin M (1992. ) Lithium toxicity associated with trichobezoar .Ann Intern Med, , 116 ,739-740

Pollak VE, Pesce A, Kant KS (1992. ) Continuous quality improvement in chronic disease: a computerized medical record enables description of a severity index to evaluate outcomes in end-stage renal disease .Am J Kidney Disease, , 19 ,514-522

Padilla B, Weiss M, Kant KS (1992. ) Henoch-Schonlein purpura in a patient with diabetic nephropathy: Case report and a review of the literature .Am J Kidney Disease, , 20 ,191-194

Pollak VE, Kant KS, Pesce A, Cathey M (1992. ) Continous quality improvement in chronic disease: Early detection of a mini-cluster of pyrogenic reactions during hemodialysis and the effect of on-line monitoring .Dialysis and Transplantation, , 21 ,330-339

Pollak VE, Thornley-Brown D, kant KS, Pesce A, Deddens JA (1993. ) A case study of a recent decline in the dalysis fatality rate .Contrib Nephrol, , 102 ,59-72

Asherson RA, Kant KS (1993. ) Antiphospholipid antibodies and the kidney .J of Rheumat, , 20 ,1267-1272

Kant KS (1994. ) Intradialytic cardiac arrhythmias: II .Seminars in Dialysis, , 7 ,58-60

Padilla B, Pollak VE, Pesce A, Kant KS, Gilinsky NH, Deddens JA (1994. ) Pancreatitis in patients with end-stage renal disease .Medicine (Baltimore), , 73 ,8-20

Peddi VR, Kant KS (1998. ) Catastrophic secondary antiphospholipid syndrome with concomitant antithrombin III deficiency .J Am Soc Nephrol, , 5 ,1882-1887

Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rodman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E (1999. ) A comparison of the calcium free-phosphate binder sevelamer hydrocholoride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients .Am J Kidney Disease, , 33 ,694-701

Book Chapter

Pesce AJ, Pollak VE, Mendoza N, Kant KS, Ford DJ (1977 ) Solid-phase enzyme-linked immunoassay for DNA-antibodies in humands

Kant KS, Pollak VE (1983 ) Pathogenesis of nephritis in systemic lupus erythematosus Glomerular Injury .(pp. 229 -244).Milan, Italy, Wichtig Editore

Kant KS, Pollak VE (1984 ) Treatment of nephritis in systemic lupus erythematosus Currenty Therapy in Nephrology and Hypertension .(pp. 139 -145).B.C Decker, Inc

Pollak VE, Kant KS (1987 ) SLE and the kidney Systemic Lupus Erthyematosus .(pp. 643 -672).New York, NY, John WIley & Sones

Glas-Greenwalt P, Kant KS, Pollak VE (1988 ) Reversal of fibrinolytic abnormalities by the snake venom ancrod (Arvic) in systemic lupus erythematosus and thrombotic thrombocytopenic purpura-like syndrome Proceeds of a Symposium on Animal Venoms and Hemostasis .(pp. 553 -569).Marcel Dekker

Kant KS (1990 ) CRF-Management Current Therapy .(pp. 640 -645).W.B. Saunders

Pollak VE, Kant KS (1990 ) Coagulation modifiers Lupus Nephritis .(pp. Chapter -14).Norwell, MA, Kluwer Academic Publishers

Pollak VE, Kant KS (1991 ) Renal Disease and SLE Systemic Lupus Erthyematosus (2nd Edition) .(pp. 683 -705).Churchill, Livingston

Padilla B, Kant KS (1993 ) Hyperkalemia 5-Minute Consult .(pp. 482 -483).Philadelphia, PA, Philadelphia Pubs

Anderson P, Kant KS (1993 ) Hypokalemia 5-Minute Consult .(pp. 502 -503).Philadelphia, PA, Philadelphia Pubs

Presentations

Invited Presentations

Kant, K (04-1997. ) Phllippine Society of Nephrology Annual Meeting,

Desch RJ, Guliants VV, Thiel SW, Duncan HJ, Kant KS, Soleimani M (2013. ) Novel Sorbents for Efficient Removal of Excess Phosphate from Blood .15th International Conference on Dialysis, Advances in CKD,

Kant, K (09-1997. ) Symposium of Angio Access, Cincinnati, OH.

Kant, K (08-1998. ) 16th Annual Convention of Alumni of All-India Institute of Medical Sciences in America,

Kant, K (03-1999. ) Annual ANNA Meeting,

Kant, K (04-1999. ) Grand Rounds at Bayview Hospital, Baltimore, MD.

Kant, K (09-1999. ) Renal Grand Rounds .University of Maryland Hospital,

Kant, K (2002. ) Cincinnati Vascular Access Symposium,

Kant, K (2004. ) Cincinnati Vascular Access Symposium,

Kant, K (2007. ) Cincinnati Vascular Access Symposium,

Kant, K (2010. ) Cincinnati Vascular Access Symposium,

Kant, K (04-2008. ) Autoantibodies: Measurement and Clinical Utility .ANNA Regional Meeting,

Kant KS, Sexton J, Kashyap M, Glas-Greenwalt P, Pollak VE (11-1984. ) Depression of endothelial cell plasminogen-activator production by lipoproteins .American Federation for Clinical Research, Chicago, IL.

Glas-Greenwalt P, Kashyap ML, Ahmad M, Kant KS, Saku K (12-1984. ) Hypertriglyceridemia is associated with depressed fibrinolysis .Am Soc Hematoglogy,

Kant KS, Sexton J, Kashyap M, Glas-Greenwalt P, Pollak VE (12-1984. ) Lipoproteins alter balance of plasminogen activator and inhibitor production by endothelial cells .Am Soc Nephrol,

Kant KS, Sexton J, Glas-Greenwalt P, Pollak VE (12-1985. ) Polyunsaturated fatty acids decrease endothelial cell production of plasminogen activator .Am Soc Nephrol,

Kim S, Kant KS, Glas-Greenwalt P, Pollak VE (05-1986. ) Successful treatment with ancrod of glomerulonephritis with glomerular thrombi is due to activation of fibrinolysis .Am Soc Invest Meeting,

Kant KS, Sexton J, Barcelli U, Pollak VE, Glas-Greenwalt P (05-1986. ) Effect of dietary eicosapentaenoic acid supplementation on monocyte function .Am Fed Clin Res,

Kant KS, Secton J, Barcelli UO, Pollak VE (05-1987. ) Eicosapentaenoic acid supplements decrease human monocyte Fc receptor activity .Annual American Federation for Clinical Research Meeting,

Wadhwa NK, Kant KS, CLune DH, Pollak VE (12-1987. ) Survival patterns in lupus nephritis with end-stage renal disease .Am Soc Nephrol,

First MR, Smith RD, Weiss MA, Schroeder TJ, Kant KS, Munda R, Stephends GW, Penn I, Alexander JW (06-1988. ) Cyclosporine associated glomerular arteriolar thrombosis following renal transplantation .7th Annual Meeting of Am Soc Transplant Phys, Chicago, IL.

Pollak VE, Hariharan S, Kant KS, Weiss MA, Wadhwa NK (07-1990. ) Diffuse proliferative lupus nephritis: Long-term observations in patients treated with ancrod .11th Int Congress Neprhol, Tokyo, Japan.

Kant KS, Glueck HI, Coots M (12-1990. ) Skin necrosis (SN) secondary to protein S(PS) deficiency: possible role of peritoneal losses in CAPD patients .Am Soc Nephrol,

Pollak VE, Pesce A, Kant KS (12-1990. ) Defining severity of illness in end-stage renal disease .Am Soc Nephrol 23rd Annual Meeting,

Rutkowski M, Kant KS, Reif MC (1994. ) Worsening of blood pressure control in an outpatient hemodialysis unit. 1986 Versus 1992 .Am Soc Nephrol 9th Scientific Meeting,

Peddi VR, Kant KS (1995. ) Effect of Hemodialysis (HD) and dialyzer reuse on protein C(PC) and protein S(SPS) levels in end stage renal disease (ESRD) patients .International Congress of Nephrology,

Peddi VR, Jenkins S, Champlin R, Woodruff L, Kant KS (1995. ) Effect of dialyzer member and dialyzer reuse on serum lipid levels in end stage renal disease (ESRD) patients on hemodialysis (HD) .Am Soc Nephrol 28th Annual Meeting ,

Peffi VR, Jenkins S, Chamaplin R, Woodruff L, Kant KS (11-1995. ) Lack of adverse effect of hemodialysis and dialyzer reuse on B2 glycoprotein levels in end stage renal disease patients .Am Soc Nephrol 28th Annual Meeting ,

Peddi VR, Kant KS (11-1996. ) Effect of dialyzer membrane and dialyzer reuse on plasma lipid levels in end stage renal disease patients on hemodialysis .Am Soc Nephrol 29th Annual Meeting,

Peddi VR, Kant KS (11-1996. ) Lack of adverse effect of hemodialysis and dialyzer reuse on B2 glycoprotein 1 levels in end stage renal disease patients .Am Soc Nephrol 29th Annual Meeting,

El-Khatib MT, Kant KS, Duncan HJ (2009. ) Pentoxifylline Improves Erythropoietin Resistance: Possible Mechanisms .Amer Soc Neph,

Kant KS, Duncan HJ, Hennessy JM (2009. ) Vitamin D Stores in CKD5: Does 25-OH D Status Influence Management of HPTH in Dialysis Patients? .Amer Soc Neph,

El-Khatib M, Kant K, Duncan H (10-2002. ) Reticulocyte hemoglobin content as a diagnostic test for IV iron administration in peritoneal dialysis patients .Am Soc Nephrol,

El-Khatib M, Kant K, Duncan H (10-2002. ) The use of reticulocyte hemoglobin content to determine IV iron administration in a hemodialysis unit .

Halukurike V, Nica R, Duncan H, Freyberg M, Hornung R, Kant K (11-2003. ) Risk factors for calciphylaxis: a case study control study .Am Soc Nephrol 36th Annual Meeting,

Hennessy J, Sorn L, Dryer K, Duncan H, Kant K (2004. ) The effect of an educational incentive on serum phosphorous values in dialysis patients .Amer Soc Neph,

El-Khatib M, Duncan H, Kant K (2006. ) Association Between Dialysis Access and C-Reactive Protein (CRP) .Amer Soc Neph, San Diego, CA.

El-Khatib M, Duncan H, Kant K (2006. ) The Usefulness of Hemoglobin Content of Reticulocytes (CHr) in Anemia Management in Dialysis Patients .Amer Soc Neph, San Diego, CA.

Duncan H, Kant K, El-Khatib M (2006. ) Hemodialysis Central Venous Catheters and Infection Control .Amer Soc Neph, San Diego, CA.

Duncan HJ, Dhingra P, Beiting M, McKinney RA, El-Khatib MT, Kant KS (2007. ) Efficacy of Lower Gentamicin Catheter Lock on Catheter Related Bacteremias and Metastatic Infections .Amer Soc Nephr , San Francisco, CA.

Athreya B, Ayodeji O, burgos CA, Ideron R, Chang I, Nossuli K, Olivero J, Sika M, Kant K (2013. ) Ferric Citrate, a Phosphate Binder, Increases Iron Stores but is not associated with Evidence of the Malnutrition-Inflammation-Cachexia Syndrome .Amer Soc Nephrology 2013, Atlanta, GA.

Poster Presentations

Peddi VR, Kant KS (11-1997. ) Lack of effect of hemodialysis and dialyzer reuse of plasma B2 glycoprotein I levels in end stage renal disease patients - results of a pilot study .Am Soc Nephrol 30th Annual Meeting,

Peddi VR, Kant KS (11-1997. ) Effect of dialyzer membrane and dialyzer reuse on plasma lipid levels in end stage renal disease patients on hemodialysis .Am Soc Nephrol 30th Annual Meeting,

Brothers S, Saylor Z, SIngh S, Kant KS (02-1999. ) Effective treatment of fungal peritonitis .19th Annual Conference on Peritoneal Dialysis,

Kant KS, Duncan H, Peterson D (11-1999. ) Phosphate independently associated with PTH in ESRD patients receiving Calcitriol .Am Soc Nephrol 32 Annual Meeting,

Qui P, Smolenski O, Fadem S, Kant K, Borneman L, Hippensteel R, WIlliams LA, Moe S (11-2003. ) Rapid Control of Secondary Hyperparathyroidism with Paricalcitol (Zemplar) Capsule in Patients on Peritoneal Dialysis .Am Soc Nephrol 36th Annual Meeting,

El-Khatib M, Kant K, Duncan H (11-2003. ) Iron Management Guided by CHr in Dialysis Patients with High Ferritin Level .Am Soc Nephrol 36th Annual Meeting,

Kant K, Duncan H, Roy-Chaudhury P (11-2003. ) Vascular Access Thrombosis: Role of Lipoprotein (a) and acute phase reactants .Am Soc Nephrol 36th Annual Meeting,

Nica R, Duncan H, Halukurike V, Kant K (11-2005. ) Is Calciphylaxis a Sign of Poor Dialysis? .Amer Soc Neph,

El-Khatib M, Duncan H, Kant K (11-2005. ) C-Reactive Protein Reticulocyte Hemoglobin Content, Inflammatory Markers in Iron Management and Erythroprotein Resistance in Dialysis Patients .Amer Soc Neph,

El-Khatib M, Kant K, Duncan H (2010. ) Factors Influencing Longevity of Dialysis Catheters .Amer Soc Neph,

Kant K, Duncan H, El-Khatib M (2010. ) Permanent Dialysis with a Cather. Fact and Fiction OR One Size Does Not Fit All .Amer Soc Neph,

Salem SM, Desch RJ, Guliants VV, Thiel SW, Duncan HJ, Kant SK (2013. ) Extracorporeal phosphate removal with a packed bed adsorber .Amer Soc Nephrology 2013, Atlanta, GA. .

Honors and Awards

1976 American Heart Association Traveling Scholarship

1989 Richard W. Vilter Award for Excellence in Resident Teaching

1995 Richard W. Vilter Award for Excellence in Resident Teaching

2000 Richard W. Vilter Award for Excellence in Resident Teaching

2010 Richard W. Vilter Award for Excellence in Resident Teaching

2000 Cincinnati Magazine: Best Physicians' List

2003 Cincinnati Magazine: Best Physicians' List

2006 Cincinnati Magazine: Best Physicians' List

2009 Cincinnati Magazine: Best Physicians' List

Keywords

cardiovascular, calcification, hemodialysis adequacy

Contact Information

Academic - Medical Sciences Building
Room G163A
Cincinnati  Ohio, 45267
Phone: 513-558-5471
Fax: 513-558-4309
shashi.kant@uc.edu